Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

115 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
KRAS-mediated upregulation of CIP2A promotes suppression of PP2A-B56α to initiate pancreatic cancer development.
Tinsley SL, Shelley RA, Mall GK, Chianis ERD, Dhiman A, Baral G, Kothandaraman H, Thoma MC, Daniel CJ, Lanman NA, di Magliano MP, Narla G, Solorio L, Dykhuizen EC, Sears RC, Allen-Petersen BL. Tinsley SL, et al. Among authors: narla g. bioRxiv [Preprint]. 2024 May 23:2023.07.01.547283. doi: 10.1101/2023.07.01.547283. bioRxiv. 2024. Update in: Oncogene. 2024 Dec;43(50):3673-3687. doi: 10.1038/s41388-024-03196-w PMID: 38826439 Free PMC article. Updated. Preprint.
Activation of the PP2A-B56α heterocomplex synergizes with venetoclax therapies in AML through BCL2 and MCL1 modulation.
Peris I, Romero-Murillo S, Martínez-Balsalobre E, Farrington CC, Arriazu E, Marcotegui N, Jiménez-Muñoz M, Alburquerque-Prieto C, Torres-López A, Fresquet V, Martínez-Climent JA, Mateos MC, Cayuela ML, Narla G, Odero MD, Vicente C. Peris I, et al. Among authors: narla g. Blood. 2023 Mar 2;141(9):1047-1059. doi: 10.1182/blood.2022016466. Blood. 2023. PMID: 36455198 Free PMC article.
Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.
Sangodkar J, Perl A, Tohme R, Kiselar J, Kastrinsky DB, Zaware N, Izadmehr S, Mazhar S, Wiredja DD, O'Connor CM, Hoon D, Dhawan NS, Schlatzer D, Yao S, Leonard D, Borczuk AC, Gokulrangan G, Wang L, Svenson E, Farrington CC, Yuan E, Avelar RA, Stachnik A, Smith B, Gidwani V, Giannini HM, McQuaid D, McClinch K, Wang Z, Levine AC, Sears RC, Chen EY, Duan Q, Datt M, Haider S, Ma'ayan A, DiFeo A, Sharma N, Galsky MD, Brautigan DL, Ioannou YA, Xu W, Chance MR, Ohlmeyer M, Narla G. Sangodkar J, et al. Among authors: narla g. J Clin Invest. 2017 Jun 1;127(6):2081-2090. doi: 10.1172/JCI89548. Epub 2017 May 15. J Clin Invest. 2017. PMID: 28504649 Free PMC article.
Therapeutic targeting of PP2A.
O'Connor CM, Perl A, Leonard D, Sangodkar J, Narla G. O'Connor CM, et al. Among authors: narla g. Int J Biochem Cell Biol. 2018 Mar;96:182-193. doi: 10.1016/j.biocel.2017.10.008. Epub 2017 Oct 26. Int J Biochem Cell Biol. 2018. PMID: 29107183 Free PMC article. Review.
Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer.
McClinch K, Avelar RA, Callejas D, Izadmehr S, Wiredja D, Perl A, Sangodkar J, Kastrinsky DB, Schlatzer D, Cooper M, Kiselar J, Stachnik A, Yao S, Hoon D, McQuaid D, Zaware N, Gong Y, Brautigan DL, Plymate SR, Sprenger CCT, Oh WK, Levine AC, Kirschenbaum A, Sfakianos JP, Sears R, DiFeo A, Ioannou Y, Ohlmeyer M, Narla G, Galsky MD. McClinch K, et al. Among authors: narla g. Cancer Res. 2018 Apr 15;78(8):2065-2080. doi: 10.1158/0008-5472.CAN-17-0123. Epub 2018 Jan 22. Cancer Res. 2018. PMID: 29358171 Free PMC article.
Sprague Dawley Rag2-Null Rats Created from Engineered Spermatogonial Stem Cells Are Immunodeficient and Permissive to Human Xenografts.
Noto FK, Adjan-Steffey V, Tong M, Ravichandran K, Zhang W, Arey A, McClain CB, Ostertag E, Mazhar S, Sangodkar J, DiFeo A, Crawford J, Narla G, Jamling TY. Noto FK, et al. Among authors: narla g. Mol Cancer Ther. 2018 Nov;17(11):2481-2489. doi: 10.1158/1535-7163.MCT-18-0156. Epub 2018 Sep 11. Mol Cancer Ther. 2018. PMID: 30206106 Free PMC article.
Targeting PP2A in cancer: Combination therapies.
Mazhar S, Taylor SE, Sangodkar J, Narla G. Mazhar S, et al. Among authors: narla g. Biochim Biophys Acta Mol Cell Res. 2019 Jan;1866(1):51-63. doi: 10.1016/j.bbamcr.2018.08.020. Epub 2018 Sep 1. Biochim Biophys Acta Mol Cell Res. 2019. PMID: 30401535 Free PMC article. Review.
The Highly Recurrent PP2A Aα-Subunit Mutation P179R Alters Protein Structure and Impairs PP2A Enzyme Function to Promote Endometrial Tumorigenesis.
Taylor SE, O'Connor CM, Wang Z, Shen G, Song H, Leonard D, Sangodkar J, LaVasseur C, Avril S, Waggoner S, Zanotti K, Armstrong AJ, Nagel C, Resnick K, Singh S, Jackson MW, Xu W, Haider S, DiFeo A, Narla G. Taylor SE, et al. Among authors: narla g. Cancer Res. 2019 Aug 15;79(16):4242-4257. doi: 10.1158/0008-5472.CAN-19-0218. Epub 2019 May 29. Cancer Res. 2019. PMID: 31142515 Free PMC article.
115 results